Posts by cowic

ANITA – Nintedanib with Ifosfamide in advanced, metastatic Soft Tissue Sarcoma (STS) Agents: Nintedanib vs. Ifosfamide Phase II Status  Closed, active Sponsor EORTC in collaboration with Boehringer Ingelheim   Further information: https://clinicaltrials.gov/ct/show/NCT02808247 or http://www.eortc.org/research_field/clinical-detail/1506/     A Phase II study comparing Nintedanib with Ifosfamide in patients with advanced, metastatic Soft Tissue Sarcoma (STS) after failure…

Trabectedin Maintenance post 1st-line in STS Agents: Trabectedin Phase III Status  Open, recruiting Sponsor EORTC in collaboration with PharmaMar  Further information: https://clinicaltrials.gov/ct/show/NCT02929394 or http://www.eortc.org/research_field/clinical-detail/1447/   Maintenance therapy with Trabectedin versus observation after first line treatment with doxorubicin of patients with advanced or metastatic soft tissue sarcoma WHO is the trial for? Adult patients (18 years…

Agents: Radiotherapy Phase II Status  Closed, active Sponsor The Netherlands Cancer Institute   Further information: https://clinicaltrials.gov/ct2/show/NCT02106312   WHO is the trial for? Adult patients with confirmed Myxoid Liposarcoma (MLS) of the soft tissue without metastasis or with only a small number of metastasis (oligometastasis) Overall health status of the patient has to be good (ECOG…

  Agents: DCC-2618 vs. placebo Phase III Status  Closed, active Sponsor Deciphera Pharmaceuticals LLC   Further information: https://clinicaltrials.gov/ct2/show/NCT03353753   WHO is the trial for? Patients with confirmed advanced or metastatic GIST with all types of mutation in KIT or PDGFRa (excluded are patients without KIT or PDGFRa mutations) Patients must have progressed on imatinib, sunitinib,…

This study evaluates the efficacy and safety of TRC105 in combination with pazopanib vs. pazopanib alone in advanced angiosarcomas. Trial name TAPPAS Agents TRC105 and pazopanib Phase III Status  Terminated Sponsor Tracon Pharmaceuticals Inc. A randomized phase III trial of TRC105 and pazopanib vs. pazopanib alone in patients with advanced angiosarcoma (TAPPAS).Further information: https://www.clinicaltrials.gov/ct2/show/study/NCT02979899?term=tracon&cond=Angiosarcoma&rank=1&show_locs=Y#locn  …

  Agents: DCC-2618 (Ripretinib) vs. Sunitinib Phase III Status  Closed for recruitment, active Sponsor Deciphera Pharmaceuticals LLC   Further information: https://clinicaltrials.gov/ct2/show/NCT03673501   WHO is the trial for? Patients with confirmed advanced or metastatic GIST Patients must have progressed on imatinib or are intolerant to imatinib; patients who had further lines of treatment after imatinib cannot…

  Patient advocacy ensures that people are heard, take action and ultimately improve situations, achieve changes or help to fulfil unmet medical needs. The projects that were entered for the “Sarcoma Advocacy in Action Award 2018” once again showed this impressively! All entries were fantastic and the jury had a hard job to decide on…

SPAEN Advocacy in Action Award 2021 announced for best projects in sarcoma patients advocacy Patient advocacy ensures that people are heard, take action and ultimately improve situations, achieve changes or help to fulfil unmet medical needs. We believe it is time to shout out about how important patient advocacy in sarcomas is – for patients,…

SPAEN Advocacy in Action Award for best projects in sarcoma patients advocacy Patient advocacy ensures that people are heard, take action and ultimately improve situations, achieve changes or help to fulfil unmet medical needs. We believe it is time to shout out about how important patient advocacy in sarcomas is – for patients, caregivers, healthcare…

by Roger Wilson, co-founder and honorary president of SPAEN and founder of Sarcoma UKResearch Involvement and Engagement, February 2018   Patient involvement in research is about adding value rather than commenting on technical quality. After 15 yearsas an involved patient in cancer research I started looking around and I found I was asking myself, where…